Abstract
Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, with median survival lingering at 12–15 months despite surgery, radiation, and chemotherapy. This article explores cutting-edge research and clinical efforts at the University of Louisville aimed at improving GBM treatment outcomes. Dr. Joseph Chen investigates the tumor microenvironment, revealing how physical properties such as stiffness and porosity drive GBM cell proliferation, migration, and resistance to apoptosis. His lab’s findings suggest that porosity, rather than stiffness alone, may be a more accurate predictor of tumor invasion and progression-free survival. Additionally, his research highlights the role of hyaluronic acid and mechanotransduction pathways in tumor behavior, suggesting novel therapeutic targets. On the clinical front, neuro-oncologist Dr. Guneet Sarai outlines current GBM treatment protocols—including the Stupp regimen, tumor-treating fields, and bevacizumab—and emphasizes the limitations of current therapies in preventing recurrence. She is leading a Phase III clinical trial evaluating the combination of lomustine with temozolomide in patients with methylated MGMT promoter status, aiming to enhance efficacy while managing severe side effects. Together, the mechanistic and clinical insights from UofL researchers highlight the need for integrative approaches that address both the biological and physical aspects of GBM. While current therapies offer limited long-term survival, emerging research in mechanobiology and drug combination strategies may pave the way for more effective, personalized treatments in the near future.
Recommended Citation
Senthil Nathan, Swetha
(2025)
"Targeting Glioblastoma: Mechanistic and Clinical Perspectives from UofL Research,"
The Cardinal Edge: Vol. 3:
Iss.
1, Article 2.
Available at:
https://ir.library.louisville.edu/tce/vol3/iss1/2
Included in
Molecular, Cellular, and Tissue Engineering Commons, Neurology Commons, Oncology Commons